Capital Fund Management S.A. Takes $1.67 Million Position in Dynavax Technologies Corporation $DVAX

Capital Fund Management S.A. purchased a new position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 168,208 shares of the biopharmaceutical company’s stock, valued at approximately $1,669,000. Capital Fund Management S.A. owned 0.14% of Dynavax Technologies as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Blair William & Co. IL boosted its holdings in shares of Dynavax Technologies by 0.3% in the second quarter. Blair William & Co. IL now owns 2,279,647 shares of the biopharmaceutical company’s stock valued at $22,614,000 after acquiring an additional 6,940 shares in the last quarter. Invesco Ltd. lifted its position in Dynavax Technologies by 33.8% in the first quarter. Invesco Ltd. now owns 2,207,631 shares of the biopharmaceutical company’s stock worth $28,633,000 after purchasing an additional 558,046 shares during the period. Woodline Partners LP boosted its stake in Dynavax Technologies by 48.4% during the 1st quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock valued at $15,289,000 after purchasing an additional 384,288 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Dynavax Technologies by 0.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,157,993 shares of the biopharmaceutical company’s stock valued at $15,019,000 after purchasing an additional 2,913 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Dynavax Technologies by 0.4% during the 2nd quarter. Nordea Investment Management AB now owns 782,248 shares of the biopharmaceutical company’s stock valued at $7,830,000 after purchasing an additional 3,171 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Trading Down 0.1%

Shares of DVAX opened at $10.96 on Friday. The business’s 50-day moving average price is $10.54 and its 200 day moving average price is $10.38. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $1.29 billion, a P/E ratio of -29.62 and a beta of 0.89. Dynavax Technologies Corporation has a 1-year low of $9.20 and a 1-year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The company had revenue of $94.88 million during the quarter, compared to analysts’ expectations of $94.00 million. Analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.